References
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7–30.
- Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288.
- Malhotra J, Malvezzi M, Negri E, et al. Risk factors for lung cancer worldwide. Eur Respir J. 2016;48(3):889–902. DOI:https://doi.org/10.1183/13993003.00359-2016.
- Bagnardi V, Rota M, Botteri E, et al. Alcohol consumption and lung cancer risk in never smokers: a meta-analysis. Ann Oncol. 2011;22(12):2631–2639. DOI:https://doi.org/10.1093/annonc/mdr027.
- Teissedre P-L, Rasines-Perea Z, Ruf J-C, et al. Effects of alcohol consumption in general, and wine in particular, on the risk of cancer development: a review. OENO One. 2020;54(4):813–832. DOI:https://doi.org/10.20870/oeno-one.2020.54.4.3569
- Mahabir S, Forman MR, Dong YQ, et al. Mineral intake and lung cancer risk in the NIH-American Association of retired persons diet and health study. Cancer Epidemiol Prev Biomarkers. 2010;19(8):1976–1983. DOI:https://doi.org/10.1158/1055-9965.EPI-10-0067.
- Mahabir S, Spitz MR, Barrera SL, et al. Dietary zinc, copper and selenium, and risk of lung cancer. Int J Cancer. 2007;120(5):1108–1115. DOI:https://doi.org/10.1002/ijc.22451.
- Zheng M. Classification and pathology of lung cancer. Surg Oncol Clin. 2016;25(3):447–468.
- Anagnostou VK, Brahmer JR. Cancer immunotherapy: a future paradigm shift in the treatment of non–small cell lung cancer. Clin Cancer Res. 2015;21(5):976–984.
- Reck M, Rodriguez-Abreu D, Robinson A, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. 2019.
- Reck M, Rodríguez-Abreu D, Robinson A, et al. KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS)≥ 50%. Ann Oncol. 2016;27:vi578. DOI:https://doi.org/10.1093/annonc/mdw435.40
- Hellmann MD, Ciuleanu T-E, Pluzanski A, et al., Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093–2104. DOI:https://doi.org/10.1056/NEJMoa1801946. .
- Aguiar PN Jr, De Mello RA, Hall P, et al. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data. Immunotherapy. 2017;9(6):499–506. DOI:https://doi.org/10.2217/imt-2016-0150.
- Ueha S, Shand FH, Matsushima K. Myeloid cell population dynamics in healthy and tumor-bearing mice. Int Immunopharmacol. 2011;11(7):783–788.
- Makarenkova VP, Bansal V, Matta BM, et al. CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J Immunol. 2006;176(4):2085–2094. DOI:https://doi.org/10.4049/jimmunol.176.4.2085.
- Mencacci A, Montagnoli C, Bacci A, et al. CD80+ Gr-1+ myeloid cells inhibit development of antifungal Th1 immunity in mice with candidiasis. J Immunol. 2002;169(6):3180–3190. DOI:https://doi.org/10.4049/jimmunol.169.6.3180.
- Finke J, Ko J, Rini B, et al. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol. 2011;11(7):856–861. DOI:https://doi.org/10.1016/j.intimp.2011.01.030.
- Binsfeld M, Muller J, Lamour V, et al. Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma. Oncotarget. 2016;7(25):37931. DOI:https://doi.org/10.18632/oncotarget.9270.
- Shi H, Zhang J, Han X, et al. Recruited monocytic myeloid‐derived suppressor cells promote the arrest of tumor cells in the premetastatic niche through an IL‐1β‐mediated increase in E‐selectin expression. Int J Cancer. 2017;140(6):1370–1383. DOI:https://doi.org/10.1002/ijc.30538.
- Husain Z, Huang Y, Seth P, et al. Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. J Immunol. 2013;191(3):1486–1495. DOI:https://doi.org/10.4049/jimmunol.1202702.
- Raber PL, Thevenot P, Sierra R, et al. Subpopulations of myeloid‐derived suppressor cells impair T cell responses through independent nitric oxide‐related pathways. Int J Cancer. 2014;134(12):2853–2864. DOI:https://doi.org/10.1002/ijc.28622.
- Kusmartsev S, Gabrilovich DI. Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J Leukoc Biol. 2003;74(2):186–196.
- Rodríguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev. 2008;222(1):180–191.
- Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol. 2010;185(4):2273–2284.
- Martin F, Apetoh L, Ghiringhelli F. Role of myeloid-derived suppressor cells in tumor immunotherapy. Immunotherapy. 2012;4(1):43–57.
- Diaz-Montero CM, Salem ML, Nishimura MI, et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58(1):49–59. DOI:https://doi.org/10.1007/s00262-008-0523-4.
- Tian J, Rui K, Tang X, et al. MicroRNA-9 regulates the differentiation and function of myeloid-derived suppressor cells via targeting Runx1. J Immunol. 2015;195(3):1301–1311. DOI:https://doi.org/10.4049/jimmunol.1500209.
- Veltman JD, Lambers ME, van Nimwegen M, et al. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC cancer. 2010;10(1):464. DOI:https://doi.org/10.1186/1471-2407-10-464.
- Srivastava MK, Zhu L, Harris-White M, et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PloS one. 2012;7(7):e40677. DOI:https://doi.org/10.1371/journal.pone.0040677.
- Shou D, Wen L, Song Z, et al. Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies. Oncotarget. 2016;7(39):64505. DOI:https://doi.org/10.18632/oncotarget.11352.
- Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol. 2018;19(2):108–119.
- Ochando J, Conde P, Utrero-Rico A, et al. Tolerogenic role of myeloid suppressor cells in organ transplantation. Front Immunol. 2019;10:374.
- Schrijver IT, Théroude C, Roger T. Myeloid-derived suppressor cells in sepsis. Front Immunol. 2019;10:327.
- Ochoa AC, Zea AH, Hernandez C, et al. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res. 2007;13(2):721s–726s. DOI:https://doi.org/10.1158/1078-0432.CCR-06-2197.
- Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res. 2001;61(12):4756–4760.
- Bronte V, Brandau S, Chen S-H, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:12150.
- Movahedi K, Guilliams M, Van Den Bossche J, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell–suppressive activity. Blood. 2008;111(8):4233–4244. DOI:https://doi.org/10.1182/blood-2007-07-099226.
- Solito S, Marigo I, Pinton L, et al. Myeloid‐derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci. 2014;1319(1):47–65. DOI:https://doi.org/10.1111/nyas.12469.
- Bronte V, Brandau S, Chen S-H, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7(1):1–10.
- Youn JI, Collazo M, Shalova IN, et al. Characterization of the nature of granulocytic myeloid‐derived suppressor cells in tumor‐bearing mice. J Leukoc Biol. 2012;91(1):167–181. DOI:https://doi.org/10.1189/jlb.0311177.
- Bergenfelz C, Leandersson K. The generation and identity of human myeloid-derived suppressor cells. Front Oncol. 2020;10:109.
- Eruslanov EB, Singhal S, Albelda SM. Mouse versus human neutrophils in cancer: a major knowledge gap. Trends Cancer. 2017;3(2):149–160.
- Trellakis S, Bruderek K, Hütte J, et al. Granulocytic myeloid-derived suppressor cells are cryosensitive and their frequency does not correlate with serum concentrations of colony-stimulating factors in head and neck cancer. Innate Immun. 2013;19(3):328–336. DOI:https://doi.org/10.1177/1753425912463618.
- Grützner E, Stirner R, Arenz L, et al. Kinetics of human myeloid-derived suppressor cells after blood draw. J Transl Med. 2016;14(1):1–7. DOI:https://doi.org/10.1186/s12967-015-0755-y.
- Kotsakis A, Harasymczuk M, Schilling B, et al. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J Immunol Methods. 2012;381(1–2):14–22. DOI:https://doi.org/10.1016/j.jim.2012.04.004.
- Kumar V, Patel S, Tcyganov E, et al. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37(3):208–220. DOI:https://doi.org/10.1016/j.it.2016.01.004.
- Yamauchi Y, Safi S, Blattner C, et al. Circulating and tumor myeloid-derived suppressor cells in resectable non–small cell lung cancer. Am J Respir Crit Care Med. 2018;198(6):777–787. DOI:https://doi.org/10.1164/rccm.201708-1707OC.
- Paschall AV, Zhang R, Qi C-F, et al. IFN regulatory factor 8 represses GM-CSF expression in T cells to affect myeloid cell lineage differentiation. J Immunol. 2015;194(5):2369–2379. DOI:https://doi.org/10.4049/jimmunol.1402412.
- Barreda DR, Hanington PC, Belosevic M. Regulation of myeloid development and function by colony stimulating factors. Dev Comp Immunol. 2004;28(5):509–554.
- Obermajer N, Muthuswamy R, Odunsi K, et al. PGE2-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. 2011;71(24):7463–7470. DOI:https://doi.org/10.1158/0008-5472.CAN-11-2449.
- Chen M-F, Kuan F-C, Yen T-C, et al. IL-6-stimulated CD11b+ CD14+ HLA-DR− myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus. Oncotarget. 2014;5(18):8716. DOI:https://doi.org/10.18632/oncotarget.2368.
- Hart K, Byrne K, Molloy M, et al. IL-10 immunomodulation of myeloid cells regulates a murine model of ovarian cancer. Front Immunol. 2011;2:29.
- Elkabets M, Ribeiro VS, Dinarello CA, et al. IL‐1β regulates a novel myeloid‐derived suppressor cell subset that impairs NK cell development and function. Eur J Immunol. 2010;40(12):3347–3357. DOI:https://doi.org/10.1002/eji.201041037.
- Liu Y, Lai L, Chen Q, et al. MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN. J Immunol. 2012;188(11):5500–5510. DOI:https://doi.org/10.4049/jimmunol.1103505.
- Pan P-Y, Wang GX, Yin B, et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood. 2008;111(1):219–228. DOI:https://doi.org/10.1182/blood-2007-04-086835.
- Kujawski M, Kortylewski M, Lee H, et al. Stat3 mediates myeloid cell–dependent tumor angiogenesis in mice. J Clin Invest. 2008;118(10):3367–3377. DOI:https://doi.org/10.1172/JCI35213.
- Xiang X, Poliakov A, Liu C, et al. Induction of myeloid‐derived suppressor cells by tumor exosomes. Int J Cancer. 2009;124(11):2621–2633. DOI:https://doi.org/10.1002/ijc.24249.
- Yu J, Wang Y, Li H, et al. Noncanonical NF-κB activation mediates STAT3-stimulated IDO up-regulation in myeloid-derived suppressor cells in breast cancer. AACR. 2014;193(5): 2574–2586 .
- Jiang M, Chen J, Zhang W, et al. Interleukin-6 trans-signaling pathway promotes immunosuppressive myeloid-derived suppressor cells via suppression of suppressor of cytokine signaling 3 in breast cancer. Front Immunol. 2017;8:1840.
- Yu J, Du W, Yan F, et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol. 2013;190(7):3783–3797. DOI:https://doi.org/10.4049/jimmunol.1201449.
- Munn DH. Blocking IDO activity to enhance anti-tumor immunity. Front Biosci (Elite Ed). 2012;4:734–745.
- Li Y, Du H, Qin Y, et al. Activation of the signal transducers and activators of the transcription 3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung. Cancer Res. 2007;67(18):8494–8503. DOI:https://doi.org/10.1158/0008-5472.CAN-07-0647.
- Wu L, Du H, Li Y, et al. Signal transducer and activator of transcription 3 (Stat3C) promotes myeloid-derived suppressor cell expansion and immune suppression during lung tumorigenesis. Am J Pathol. 2011;179(4):2131–2141. DOI:https://doi.org/10.1016/j.ajpath.2011.06.028.
- Zhao D, Pan C, Sun J, et al. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene. 2015;34(24):3107–3119. DOI:https://doi.org/10.1038/onc.2014.257.
- Bartoli M, Platt D, Lemtalsi T, et al. VEGF differentially activates STAT3 in microvascular endothelial cells. FASEB J. 2003;17(11):1562–1564. DOI:https://doi.org/10.1096/fj.02-1084fje.
- Zhou J, Qu Z, Sun F, et al. Myeloid STAT3 promotes lung tumorigenesis by transforming tumor immunosurveillance into tumor-promoting inflammation. Cancer Immunol Res. 2017;5(3):257–268. DOI:https://doi.org/10.1158/2326-6066.CIR-16-0073.
- Marigo I, Bosio E, Solito S, et al. Tumor-induced tolerance and immune suppression depend on the C/EBPβ transcription factor. Immunity. 2010;32(6):790–802. DOI:https://doi.org/10.1016/j.immuni.2010.05.010.
- Youn J-I, Kumar V, Collazo M, et al. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol. 2013;14(3):211. DOI:https://doi.org/10.1038/ni.2526.
- Ryzhov S, Novitskiy SV, Goldstein AE, et al. Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+ Gr1+ cells. J Immunol. 2011;187(11):6120–6129. DOI:https://doi.org/10.4049/jimmunol.1101225.
- Wang S-H, Lu Q-Y, Guo Y-H, et al. The blockage of Notch signalling promoted the generation of polymorphonuclear myeloid-derived suppressor cells with lower immunosuppression. Eur J Cancer. 2016;68:90–105.
- van Deventer HW, Burgents JE, Wu QP, et al. The inflammasome component NLRP3 impairs antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived suppressor cells. Cancer Res. 2010;70(24):10161–10169. DOI:https://doi.org/10.1158/0008-5472.CAN-10-1921.
- Kusmartsev S, Gabrilovich DI. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol. 2005;174(8):4880–4891.
- Munera V, Popovic PJ, Bryk J, et al. Stat 6-dependent induction of myeloid derived suppressor cells after physical injury regulates nitric oxide response to endotoxin. Ann Surg. 2010;251(1):120–126. DOI:https://doi.org/10.1097/SLA.0b013e3181bfda1c.
- Rodriguez PC, Hernandez CP, Quiceno D, et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med. 2005;202(7):931–939. DOI:https://doi.org/10.1084/jem.20050715.
- Condamine T, Kumar V, Ramachandran IR, et al. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R–mediated apoptosis. J Clin Invest. 2014;124(6):2626–2639. DOI:https://doi.org/10.1172/JCI74056.
- Bronte V, Serafini P, De Santo C, et al. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol. 2003;170(1):270–278. DOI:https://doi.org/10.4049/jimmunol.170.1.270.
- Chiu DK-C, Tse AP-W, Xu IM-J, et al. Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma. Nat Commun. 2017;8(1):517. DOI:https://doi.org/10.1038/s41467-017-00530-7.
- Chiu DKC, Xu IMJ, Lai RKH, et al. Hypoxia induces myeloid‐derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C‐C motif) ligand 26. Hepatology. 2016;64(3):797–813. DOI:https://doi.org/10.1002/hep.28655.
- Umansky V, Sevko A. Tumor microenvironment and myeloid-derived suppressor cells. Cancer Microenviron. 2013;6(2):169–177. DOI:https://doi.org/10.1007/s12307-012-0126-7
- Chun E, Lavoie S, Michaud M, et al. CCL2 promotes colorectal carcinogenesis by enhancing polymorphonuclear myeloid-derived suppressor cell population and function. Cell Rep. 2015;12(2):244–257. DOI:https://doi.org/10.1016/j.celrep.2015.06.024.
- Alfaro C, Teijeira A, Oñate C, et al. Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs). Clin Cancer Res. 2016;22(15):3924–3936. DOI:https://doi.org/10.1158/1078-0432.CCR-15-2463.
- Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775–787. DOI:https://doi.org/10.1016/j.cell.2008.05.009.
- Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol. 2011;11(12):852.
- Takahashi T, Kuniyasu Y, Toda M, et al. Immunologic self-tolerance maintained by CD25+ CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol. 1998;10(12):1969–1980. DOI:https://doi.org/10.1093/intimm/10.12.1969.
- Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007;450(7169):566. DOI:https://doi.org/10.1038/nature06306.
- Camisaschi C, Casati C, Rini F, et al. LAG-3 expression defines a subset of CD4+ CD25highFoxp3+ regulatory T cells that are expanded at tumor sites. J Immunol. 2010;184(11):6545–6551. DOI:https://doi.org/10.4049/jimmunol.0903879.
- Conrad C, Gregorio J, Wang Y-H, et al. Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3+ T-regulatory cells. Cancer Res. 2012;72(20):5240–5249. DOI:https://doi.org/10.1158/0008-5472.CAN-12-2271.
- Kamada T, Togashi Y, Tay C, et al. PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Nat Acad Sci. 2019;116(20):9999–10008. DOI:https://doi.org/10.1073/pnas.1822001116.
- Uyttenhove C, Pilotte L, Théate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat Med. 2003;9(10):1269. DOI:https://doi.org/10.1038/nm934.
- Grohmann U, Orabona C, Fallarino F, et al. CTLA-4–Ig regulates tryptophan catabolism in vivo. Nat Immunol. 2002;3(11):1097. DOI:https://doi.org/10.1038/ni846.
- Maj T, Wang W, Crespo J, et al. Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat Immunol. 2017 Dec;18(12):1332–1341. DOI:https://doi.org/10.1038/ni.3868.
- Beier UH. Apoptotic Regulatory T Cells Retain Suppressive Function through Adenosine. Cell Metab. 2018;27(1):5–7.
- Fujimura T, Ring S, Umansky V, et al. Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas. J Invest Dermatol. 2012;132(4):1239–1246. DOI:https://doi.org/10.1038/jid.2011.416.
- Zhang Z, Liu S, Zhang B, et al. T cell dysfunction and exhaustion in cancer. Front Cell Dev Biol. 2020;8:17.
- Shen T, Zhou L, Shen H, et al. Prognostic value of programmed cell death protein 1 expression on CD8+ T lymphocytes in pancreatic cancer. Sci Rep. 2017;7(1):7848. DOI:https://doi.org/10.1038/s41598-017-08479-9.
- He J, Hu Y, Hu M, et al. Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer. Sci Rep. 2015;5(1):1–9.
- Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 2012;72(9):2162–2171.
- Mantovani A, Marchesi F, Malesci A, et al. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14(7):399. DOI:https://doi.org/10.1038/nrclinonc.2016.217.
- Pan P-Y, Ma G, Weber KJ, et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res. 2010;70(1):99–108. DOI:https://doi.org/10.1158/0008-5472.CAN-09-1882.
- Brosnan ME, Brosnan JT. Renal arginine metabolism. J Nutr. 2004;134(10):2791S–2795S.
- Raber P, Ochoa AC, Rodríguez PC. Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest. 2012;41(6–7):614–634.
- Gray MJ, Poljakovic M, Kepka-Lenhart D, et al. Induction of arginase I transcription by IL-4 requires a composite DNA response element for STAT6 and C/EBPβ. Gene. 2005;353(1):98–106. DOI:https://doi.org/10.1016/j.gene.2005.04.004.
- Rodriguez PC, Ochoa AC, Al-Khami AA. Arginine metabolism in myeloid cells shapes innate and adaptive immunity. Front Immunol. 2017;8:93.
- Holán V, Pindjáková J, Krulová M, et al. Production of nitric oxide during graft rejection is regulated by the Th1/Th2 balance, the arginase activity, and L-arginine metabolism. Transplantation. 2006;81(12):1708–1715. DOI:https://doi.org/10.1097/01.tp.0000226067.89690.2b.
- Ochoa JB, Strange J, Kearney P, et al. Effects of L‐arginine on the proliferation of T lymphocyte subpopulations. J Parenteral Enteral Nutr. 2001;25(1):23–29. DOI:https://doi.org/10.1177/014860710102500123.
- Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood. 2007;109(4):1568–1573.
- Fletcher M, Ramirez ME, Sierra RA, et al. l-Arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells. Cancer Res. 2015;75(2):275–283. DOI:https://doi.org/10.1158/0008-5472.CAN-14-1491.
- Rodriguez PC, Zea AH, Culotta KS, et al. Regulation of t cell receptor cd3ζ chain expression byl-arginine. J Biol Chem. 2002;277(24):21123–21129. DOI:https://doi.org/10.1074/jbc.M110675200.
- Bian Z, Abdelaal AM, Shi L, et al. Arginase‐1 is neither constitutively expressed in nor required for myeloid‐derived suppressor cell‐mediated inhibition of T‐cell proliferation. Eur J Immunol. 2018;48(6):1046–1058. DOI:https://doi.org/10.1002/eji.201747355.
- Gmünder H, Hp ECK, Dröge W. Low membrane transport activity for cystine in resting and mitogenically stimulated human lymphocyte preparations and human T cell clones. Eur J Biochem. 1991;201(1):113–117.
- Angelini G, Gardella S, Ardy M, et al. Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proc Nat Acad Sci. 2002;99(3):1491–1496. DOI:https://doi.org/10.1073/pnas.022630299.
- Srivastava MK, Sinha P, Clements VK, et al. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 2010;70(1):68–77. DOI:https://doi.org/10.1158/0008-5472.CAN-09-2587.
- Sakakura Y, Sato H, Shiiya A, et al. Expression and function of cystine/glutamate transporter in neutrophils. J Leukoc Biol. 2007;81(4):974–982. DOI:https://doi.org/10.1189/jlb.0606385.
- Vincent J, Mignot G, Chalmin F, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell–dependent antitumor immunity. Cancer Res. 2010;70(8):3052–3061. DOI:https://doi.org/10.1158/0008-5472.CAN-09-3690.
- Munn DH, Shafizadeh E, Attwood JT, et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med. 1999;189(9):1363–1372. DOI:https://doi.org/10.1084/jem.189.9.1363.
- Schwarcz R. The kynurenine pathway of tryptophan degradation as a drug target. Curr Opin Pharmacol. 2004;4(1):12–17.
- Mellor AL, Munn DH. Tryptophan catabolism prevents maternal T cells from activating lethal anti-fetal immune responses. J Reprod Immunol. 2001;52(1–2):5–13.
- Bartok O, Pataskar A, Nagel R, et al. Anti-tumour immunity induces aberrant peptide presentation in melanoma. Nature. 2021;590(7845):332–337. DOI:https://doi.org/10.1038/s41586-020-03054-1.
- Holmgaard RB, Zamarin D, Li Y, et al. Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner. Cell Rep. 2015;13(2):412–424. DOI:https://doi.org/10.1016/j.celrep.2015.08.077.
- Smith C, Chang MY, Parker KH, et al. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov. 2012;2(8):722–735. DOI:https://doi.org/10.1158/2159-8290.CD-12-0014.
- Schafer CC, Wang Y, Hough KP, et al. Indoleamine 2, 3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment. Oncotarget. 2016;7(46):75407. DOI:https://doi.org/10.18632/oncotarget.12249.
- Pryor WA, Squadrito GL. The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. Am J Physiol Lung Cell Mol Physiol. 1995;268(5):L699–L722.
- Harari O, Liao JK. Inhibition of MHC II gene transcription by nitric oxide and antioxidants. Curr Pharm Des. 2004;10(8):893–898.
- Bingisser RM, Tilbrook PA, Holt PG, et al. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J Immunol. 1998;160(12):5729–5734.
- Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol. 2005;5(8):641.
- Jayaraman P, Parikh F, Lopez-Rivera E, et al. Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release. J Immunol. 2012;188(11):5365–5376. DOI:https://doi.org/10.4049/jimmunol.1103553.
- Nagaraj S, Gupta K, Pisarev V, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007;13(7):828–835. DOI:https://doi.org/10.1038/nm1609.
- Sareila O, Kelkka T, Pizzolla A, et al. Nox2 complex–derived ROS as immune regulators. Antioxid Redox Signal. 2011;15(8):2197–2208. DOI:https://doi.org/10.1089/ars.2010.3635.
- Corzo CA, Cotter MJ, Cheng P, et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol. 2009;182(9):5693–5701. DOI:https://doi.org/10.4049/jimmunol.0900092.
- Lim JW, Kim H, Kim KH. Nuclear factor-κB regulates cyclooxygenase-2 expression and cell proliferation in human gastric cancer cells. Lab Invest. 2001;81(3):349–360.
- Cheng P, Corzo CA, Luetteke N, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med. 2008;205(10):2235–2249. DOI:https://doi.org/10.1084/jem.20080132.
- Sinha P, Clements VK, Fulton AM, et al. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 2007;67(9):4507–4513. DOI:https://doi.org/10.1158/0008-5472.CAN-06-4174.
- Rastad JL, Green WR. Myeloid-derived suppressor cells in murine AIDS inhibit B-cell responses in part via soluble mediators including reactive oxygen and nitrogen species, and TGF-β. Virology. 2016;499:9–22.
- Sauer H, Wartenberg M, Hescheler J. Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell physiol biochem. 2001;11(4):173–186.
- Chen Y, Zhang H, Zhou HJ, et al. Mitochondrial redox signaling and tumor progression. Cancers (Basel). 2016;8(4):40. DOI:https://doi.org/10.3390/cancers8040040.
- Liu Y, Wei J, Guo G, et al. Norepinephrine-induced myeloid-derived suppressor cells block T-cell responses via generation of reactive oxygen species. Immunopharmacol Immunotoxicol. 2015;37(4):359–365. DOI:https://doi.org/10.3109/08923973.2015.1059442.
- Kamiński MM, Röth D, Sass S, et al. Manganese superoxide dismutase: a regulator of T cell activation-induced oxidative signaling and cell death. Biochim Biophys Acta-Mol Cell Res. 2012;1823(5):1041–1052. DOI:https://doi.org/10.1016/j.bbamcr.2012.03.003.
- Hubert MT, Thayer TC, Steele C, et al. NADPH oxidase deficiency regulates Th lineage commitment and modulates autoimmunity. J Immunol. 2010;185(9):5247–5258. DOI:https://doi.org/10.4049/jimmunol.1001472.
- Moses HL, Roberts AB, Derynck R. The discovery and early days of TGF-β: a historical perspective. Cold Spring Harb Perspect Biol. 2016;8(7):a021865.
- Huang B, Pan P-Y, Li Q, et al. Gr-1+ CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006;66(2):1123–1131. DOI:https://doi.org/10.1158/0008-5472.CAN-05-1299.
- Lee C-R, Kwak Y, Yang T, et al. Myeloid-derived suppressor cells are controlled by regulatory T cells via TGF-β during murine colitis. Cell Rep. 2016;17(12):3219–3232. DOI:https://doi.org/10.1016/j.celrep.2016.11.062.
- Li H, Han Y, Guo Q, et al. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-β1. J Immunol. 2009;182(1):240–249. DOI:https://doi.org/10.4049/jimmunol.182.1.240.
- Pickup M, Novitskiy S, Moses HL. The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer. 2013;13(11):788.
- Lee C-R, Lee W, Cho SK, et al. Characterization of multiple cytokine combinations and TGF-β on differentiation and functions of myeloid-derived suppressor cells. Int J Mol Sci. 2018;19(3):869. DOI:https://doi.org/10.3390/ijms19030869.
- Zhang B. CD73: a novel target for cancer immunotherapy. Cancer Res. 2010;70(16):6407–6411.
- Suh Y, Yoon C, Kim R, et al. Claudin-1 induces epithelial–mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells. Oncogene. 2013;32(41):4873–4882. DOI:https://doi.org/10.1038/onc.2012.505.
- Li J, Wang L, Chen X, et al. CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancer. Oncoimmunology. 2017;6(6):e1320011. DOI:https://doi.org/10.1080/2162402X.2017.1320011.
- Juneja VR, McGuire KA, Manguso RT, et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017;214(4):895–904. DOI:https://doi.org/10.1084/jem.20160801.
- Kuang D-M, Zhao Q, Peng C, et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med. 2009;206(6):1327–1337. DOI:https://doi.org/10.1084/jem.20082173.
- Iwata T, Kondo Y, Kimura O, et al. PD-L1+ MDSCs are increased in HCC patients and induced by soluble factor in the tumor microenvironment. Sci Rep. 2016;6:39296.
- Chen X, Wang L, Li P, et al. Dual TGF‐β and PD‐1 blockade synergistically enhances MAGE‐A3‐specific CD8+ T cell response in esophageal squamous cell carcinoma. Int J Cancer. 2018;143(10):2561–2574. DOI:https://doi.org/10.1002/ijc.31730.
- Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med. 1996;183(6):2533–2540.
- Liu Y, Yu Y, Yang S, et al. Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells. Cancer Immunol Immunother. 2009;58(5):687–697. DOI:https://doi.org/10.1007/s00262-008-0591-5.
- Ortiz ML, Lu L, Ramachandran I, et al. Myeloid-derived suppressor cells in the development of lung cancer. Cancer Immunol Res. 2014;2(1):50–58. DOI:https://doi.org/10.1158/2326-6066.CIR-13-0129.
- Tian T, Gu X, Zhang B, et al. Increased circulating CD14 (+) HLA-DR-/low myeloid-derived suppressor cells are associated with poor prognosis in patients with small-cell lung cancer. Cancer Biomarkers. 2015;15(4):425–432. DOI:https://doi.org/10.3233/CBM-150473.
- Antonia SJ, Mirza N, Fricke I, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res. 2006;12(3):878–887. DOI:https://doi.org/10.1158/1078-0432.CCR-05-2013.
- Vetsika E-K, Koinis F, Gioulbasani M, et al. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients. J Immunol Res. 2014;659294.
- Heuvers ME, Muskens F, Bezemer K, et al. Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patients. Lung Cancer. 2013;81(3):468–474. DOI:https://doi.org/10.1016/j.lungcan.2013.06.005.
- Wang S, Fu Y, Ma K, et al. The significant increase and dynamic changes of the myeloid-derived suppressor cells percentage with chemotherapy in advanced NSCLC patients. Clin Transl Oncol. 2014;16(7):616–622. DOI:https://doi.org/10.1007/s12094-013-1125-y.
- Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480–489.
- Gabrilovich DI, Velders MP, Sotomayor EM, et al. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol. 2001;166(9):5398–5406. DOI:https://doi.org/10.4049/jimmunol.166.9.5398.
- Nefedova Y, Fishman M, Sherman S, et al. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res. 2007;67(22):11021–11028. DOI:https://doi.org/10.1158/0008-5472.CAN-07-2593.
- Tobin RP, Jordan KR, Robinson WA, et al. Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab. Int Immunopharmacol. 2018 Oct;63:282–291.
- Arrieta O, González-de La Rosa CH, Aréchaga-Ocampo E, et al., Randomized phase II trial of All-trans-retinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line treatment in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(21):3463–3471. DOI:https://doi.org/10.1200/JCO.2009.26.6452. .
- Iclozan C, Antonia S, Chiappori A, et al. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother. 2013;62(5):909–918. DOI:https://doi.org/10.1007/s00262-013-1396-8.
- Li R, Salehi-Rad R, Crosson W, et al. Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Non–Small Cell Lung Cancer. Cancer Res. 2021;81(12):3295–3308. DOI:https://doi.org/10.1158/0008-5472.CAN-20-3564.
- Ma J, Liu Y, Li Y, et al. Differential role of all‐trans retinoic acid in promoting the development of CD4+ and CD8+ regulatory T cells. J Leukoc Biol. 2014;95(2):275–283. DOI:https://doi.org/10.1189/jlb.0513297.
- Testa U, Masciulli R, Tritarelli E, et al. Transforming growth factor-beta potentiates vitamin D3-induced terminal monocytic differentiation of human leukemic cell lines. J Immunol. 1993;150(6):2418–2430.
- Chen P-T, Hsieh -C-C, Wu C-T, et al. 1α, 25-dihydroxyvitamin D3 inhibits esophageal squamous cell carcinoma progression by reducing IL6 signaling. Mol Cancer Ther. 2015;14(6):1365–1375. DOI:https://doi.org/10.1158/1535-7163.MCT-14-0952.
- Fleet JC, DeSmet M, Johnson R, et al. Vitamin D and cancer: a review of molecular mechanisms. Biochem J. 2012;441(1):61–76. DOI:https://doi.org/10.1042/BJ20110744.
- Fleet J, Burcham G, Calvert R, et al. 1α, 25 Dihydroxyvitamin D (1, 25 (OH) 2D) inhibits the T cell suppressive function of myeloid derived suppressor cells (MDSC). J Steroid Biochem Mol Biol. 2020;198:105557.
- Michels T, Shurin GV, Naiditch H, et al. Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner. J Immunotoxicol. 2012;9(3):292–300. DOI:https://doi.org/10.3109/1547691X.2011.642418.
- Merriman R, Hertel L, Schultz R, et al. Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models. Invest New Drugs. 1996;14(3):243–247. DOI:https://doi.org/10.1007/BF00194526.
- Suzuki E, Kapoor V, Jassar AS, et al. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 2005;11(18):6713–6721. DOI:https://doi.org/10.1158/1078-0432.CCR-05-0883.
- Le HK, Graham L, Cha E, et al. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol. 2009;9(7–8):900–909. DOI:https://doi.org/10.1016/j.intimp.2009.03.015.
- Ko H-J, Kim Y-J, Kim Y-S, et al. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 2007;67(15):7477–7486. DOI:https://doi.org/10.1158/0008-5472.CAN-06-4639.
- Wang Z, Till B, Gao Q. Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells. Oncoimmunology. 2017;6(7):e1331807.
- Karachi A, Yang C, Dastmalchi F, et al. Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition. Neuro Oncol. 2019;21(6):730–741. DOI:https://doi.org/10.1093/neuonc/noz015.
- Owen DH, Benner B, Pilcher C, et al. Deep and durable response to Nivolumab and Temozolomide in small-cell lung cancer associated with an early decrease in myeloid-derived suppressor cells. Clin Lung Cancer. 2021;22(4):e487–e497. DOI:https://doi.org/10.1016/j.cllc.2020.10.018.
- Cao Y, Feng Y, Zhang Y, et al. L-Arginine supplementation inhibits the growth of breast cancer by enhancing innate and adaptive immune responses mediated by suppression of MDSCs in vivo. BMC cancer. 2016;16(1):343. DOI:https://doi.org/10.1186/s12885-016-2376-0.
- Zheng Y, Xu M, Li X, et al. Cimetidine suppresses lung tumor growth in mice through proapoptosis of myeloid-derived suppressor cells. Mol Immunol. 2013;54(1):74–83. DOI:https://doi.org/10.1016/j.molimm.2012.10.035.
- Srinivasan S, Ranga RS, Burikhanov R, et al. Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells. Cancer Res. 2007;67(1):246–253. DOI:https://doi.org/10.1158/0008-5472.CAN-06-2430.
- Oh JH, Lee T-J, Kim SH, et al. Induction of apoptosis by withaferin A in human leukemia U937 cells through down-regulation of Akt phosphorylation. Apoptosis. 2008;13(12):1494–1504. DOI:https://doi.org/10.1007/s10495-008-0273-y.
- Mohan R, Hammers HJ, Bargagna-Mohan P, et al. Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis. 2004;7(2):115–122. DOI:https://doi.org/10.1007/s10456-004-1026-3.
- Koduru S, Kumar R, Srinivasan S, et al. Notch-1 inhibition by Withaferin-A: a therapeutic target against colon carcinogenesis. Mol Cancer Ther. 2010;9(1):202–210. DOI:https://doi.org/10.1158/1535-7163.MCT-09-0771.
- Sinha P, Ostrand-Rosenberg S. Myeloid-derived suppressor cell function is reduced by Withaferin A, a potent and abundant component of Withania somnifera root extract. Cancer Immunol Immunother. 2013;62(11):1663–1673.
- Hsu JH-M, Chang PM-H, Cheng T-S, et al. Identification of withaferin a as a potential candidate for anti-cancer therapy in non-small cell lung cancer. Cancers (Basel). 2019;11(7):1003. DOI:https://doi.org/10.3390/cancers11071003.
- Talmadge JE, Hood KC, Zobel LC, et al. Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion. Int Immunopharmacol. 2007;7(2):140–151. DOI:https://doi.org/10.1016/j.intimp.2006.09.021.
- Serafini P, Meckel K, Kelso M, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med. 2006;203(12):2691–2702. DOI:https://doi.org/10.1084/jem.20061104.
- Wen L, Tian-Cong W, Dong-Mei H, et al. Carnosic acid enhances the anti-lung cancer effect of cisplatin by inhibiting myeloid-derived suppressor cells. Chin J Nat Med. 2018;16(12):907–915. DOI:https://doi.org/10.1016/S1875-5364(18)30132-8.
- Sawant A, Schafer CC, Jin TH, et al. Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways. Cancer Res. 2013;73(22):6609–6620. DOI:https://doi.org/10.1158/0008-5472.CAN-13-0987.
- Qu P, Shelley WC, Yoder MC, et al. Critical roles of lysosomal acid lipase in myelopoiesis. Am J Pathol. 2010;176(5):2394–2404. DOI:https://doi.org/10.2353/ajpath.2010.091063.
- Qu P, Shelley W, and Yoder M, et al., editors. Critical Roles Of Lysosomal Acid Lipase In Myelopoiesis And Lung Pathogenesis. Am J Respir Crit Care Med. 2010;176(5):2394–404 ;amer thoracic soc 61 broadway, FL 4, NEW YORK, NY 10006 USA.
- Yan C, Lian X, Li Y, et al. Macrophage-specific expression of human lysosomal acid lipase corrects inflammation and pathogenic phenotypes in lal−/− mice. Am J Pathol. 2006;169(3):916–926. DOI:https://doi.org/10.2353/ajpath.2006.051327.
- Melani C, Sangaletti S, Barazzetta FM, et al. Amino-biphosphonate–mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res. 2007;67(23):11438–11446. DOI:https://doi.org/10.1158/0008-5472.CAN-07-1882.
- Horikawa N, Abiko K, Matsumura N, et al. Expression of vascular endothelial growth factor in ovarian cancer inhibits tumor immunity through the accumulation of myeloid-derived suppressor cells. Clin Cancer Res. 2017;23(2):587–599. DOI:https://doi.org/10.1158/1078-0432.CCR-16-0387.
- Koinis F, Vetsika EK, Aggouraki D, et al. Effect of first-line treatment on myeloid-derived suppressor cells’ subpopulations in the peripheral blood of patients with non–small cell lung cancer. J Thorac Oncol. 2016;11(8):1263–1272. DOI:https://doi.org/10.1016/j.jtho.2016.04.026.
- Feng P-H, Chen K-Y, Huang Y-C, et al. Bevacizumab reduces S100A9-positive MDSCs linked to intracranial control in patients with EGFR-mutant lung adenocarcinoma. J Thorac Oncol. 2018;13(7):958–967. DOI:https://doi.org/10.1016/j.jtho.2018.03.032.
- Basu S, Nagy JA, Pal S, et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med. 2001;7(5):569–574. DOI:https://doi.org/10.1038/87895.
- Hoeppner LH, Wang Y, Sharma A, et al. Dopamine D2 receptor agonists inhibit lung cancer progression by reducing angiogenesis and tumor infiltrating myeloid derived suppressor cells. Mol Oncol. 2015;9(1):270–281. DOI:https://doi.org/10.1016/j.molonc.2014.08.008.
- Priceman SJ, Sung JL, Shaposhnik Z, et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood J Am Soc Hematol. 2010;115(7):1461–1471.
- Adah D, Yang Y, Liu Q, et al. Plasmodium infection inhibits the expansion and activation of MDSCs and Tregs in the tumor microenvironment in a murine Lewis lung cancer model. Cell Commun Signaling. 2019;17(1):32. DOI:https://doi.org/10.1186/s12964-019-0342-6.
- Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723. DOI:https://doi.org/10.1056/NEJMoa1003466.
- Morgensztern D, Herbst RS. Nivolumab and pembrolizumab for non–small cell lung cancer. Clin Cancer Res. 2016;22(15):3713–3717.
- Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–265. DOI:https://doi.org/10.1016/S0140-6736(16)32517-X.
- Ostrand-Rosenberg S, Fenselau C. Myeloid-derived suppressor cells: immune-suppressive cells that impair antitumor immunity and are sculpted by their environment. J Immunol. 2018;200(2):422–431.
- Kim HR, Park S-M, Seo S-U, et al. The Ratio of Peripheral Regulatory T Cells to Lox-1+ Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti–PD-1 Therapy in Patients with Non–Small Cell Lung Cancer. Am J Respir Crit Care Med. 2019;199(2):243–246. DOI:https://doi.org/10.1164/rccm.201808-1502LE.
- Li A, Barsoumian HB, Schoenhals JE, et al. Indoleamine 2, 3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells. Cancer Lett. 2018;431:54–63.
- Long GV, Dummer R, Hamid O, et al., Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 2019;20(8):1083–1097. DOI:https://doi.org/10.1016/S1470-2045(19)30274-8. .
- Wang Y, Zhang X, Yang L, et al. Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer. J Bone Oncol. 2018;11:27–32.
- All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT04919369?cond=NCT04919369&draw=2&rank=1.
- Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy [Internet] [cited 2000 Feb 29] . Available from: https://clinicaltrials.gov/ct2/show/NCT03302247?cond=NCT03302247&draw=2&rank=1.